Renal Cell Carcinoma Market: Growth to Reach USD 1005.11 Million by 2029

RCC has a five-year survival rate of above 70%, according to the National Cancer Institute. Renal cell carcinoma is one of the most rapidly growing solid tumor cancers. The clinical paradigm that governs both renal cell carcinoma comprehension and treatment has changed dramatically during the last few decades. Renal cell carcinoma is the eighth most prevalent cancer in adults, accounting for between 3% and 4% of all new cancer cases worldwide. Various renowned research institutes have calculated that renal cell carcinoma is the seventh most prevalent cancer in men and the ninth most common cancer in women.
Recent Development

In January 2021, the Food and Drug Administration had announced the approval of combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC). Nivolumab 240 mg every two weeks (30-minute intravenous infusion) or 480 mg every four weeks (30-minute intravenous infusion) in conjunction with cabozantinib 40 mg orally once day without food until disease progression or unacceptable toxicity is achieved is the suggested dosage.

Some of the major players operating in the renal cell carcinoma market are:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)

Get More Info : https://www.databridgemarketresearch.com/reports/global-renal-cell-carcinoma-market

Renal Cell Carcinoma Market Regional Analysis/Insights

The renal cell carcinoma market is analysed and market size insights and trends are provided by country, treatment, diagnosis, type, dosage forms, route of administration, end-users and distribution channel as referenced above.

The countries covered in the renal cell carcinoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Data Bridge Market Research analyses that the renal cell carcinoma market was valued at USD 635.40 million in 2021 and is expected to reach USD 1005.11 million by 2029, registering a CAGR of 5.90% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

More Links:

https://dbmr232343.blogspot.com/2023/07/north-america-heart-valve-devices.html

https://dbmr232343.blogspot.com/2023/07/vitrectomy-machines-market-industry.html

https://dbmr232343.blogspot.com/2023/07/whole-slide-imaging-market-industry.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.